GLS

Across TCGA pan-cancer cohorts, GLS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLS data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GLS mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLS expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where GLS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.297	0.647	.004	29	view →
PDAC	DFS	Tertile	IV	0.217	0.550	.024	10	view →
HNSC	OS	Tertile	IV	0.616	0.909	.010	9	view →
LUAD	DFS	Median	II,III,IV	0.722	0.185	.013	3	view →
GBM	DFS	Quartile	All	0.861	0.679	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GLS–CCRCC (DFS)

Open the CCRCC breakdown →